- Report
- June 2025
- 150 Pages
Global
From €5317EUR$5,950USD£4,549GBP
- Report
- September 2024
- 120 Pages
Global
From €5317EUR$5,950USD£4,549GBP
- Report
- May 2023
- 171 Pages
Global
From €5317EUR$5,950USD£4,549GBP
- Report
- November 2024
- 110 Pages
Global
From €5317EUR$5,950USD£4,549GBP
- Report
- February 2023
- 126 Pages
Global
From €5317EUR$5,950USD£4,549GBP
- Report
- August 2025
- 187 Pages
Global
From €3168EUR$3,545USD£2,710GBP
€3520EUR$3,939USD£3,011GBP
- Report
- August 2025
- 196 Pages
Global
From €3168EUR$3,545USD£2,710GBP
€3520EUR$3,939USD£3,011GBP
- Report
- August 2025
- 192 Pages
Global
From €3168EUR$3,545USD£2,710GBP
€3520EUR$3,939USD£3,011GBP
- Report
- August 2025
- 199 Pages
Global
From €3168EUR$3,545USD£2,710GBP
€3520EUR$3,939USD£3,011GBP
- Report
- August 2025
- 193 Pages
Global
From €3168EUR$3,545USD£2,710GBP
€3520EUR$3,939USD£3,011GBP
- Report
- August 2025
- 181 Pages
Global
From €3168EUR$3,545USD£2,710GBP
€3520EUR$3,939USD£3,011GBP
- Report
- August 2025
- 195 Pages
Global
From €3168EUR$3,545USD£2,710GBP
€3520EUR$3,939USD£3,011GBP
- Report
- August 2025
- 189 Pages
Global
From €3168EUR$3,545USD£2,710GBP
€3520EUR$3,939USD£3,011GBP
- Report
- August 2025
- 197 Pages
Global
From €3168EUR$3,545USD£2,710GBP
€3520EUR$3,939USD£3,011GBP
- Report
- August 2025
- 181 Pages
Global
From €3168EUR$3,545USD£2,710GBP
€3520EUR$3,939USD£3,011GBP
- Report
- August 2025
- 196 Pages
Global
From €3168EUR$3,545USD£2,710GBP
€3520EUR$3,939USD£3,011GBP
- Report
- July 2025
- 200 Pages
Europe
From €2225EUR$2,490USD£1,904GBP
- Report
- August 2025
- 100 Pages
Global
From €4379EUR$4,900USD£3,746GBP
- Report
- August 2025
- 100 Pages
Global
From €4379EUR$4,900USD£3,746GBP
- Report
- August 2025
- 100 Pages
Global
From €4379EUR$4,900USD£3,746GBP
![Loading Indicator](/images/loading.gif")
The Liver and Kidney Disorders Drugs market is a segment of the pharmaceutical industry that focuses on the development and production of drugs to treat diseases and disorders of the liver and kidneys. These drugs are used to treat a variety of conditions, including hepatitis, cirrhosis, kidney failure, and other kidney-related diseases. The market is highly competitive, with many companies vying for market share.
The market is driven by the increasing prevalence of liver and kidney diseases, as well as the development of new treatments and technologies. Additionally, the rising demand for better treatments and the increasing availability of generic drugs are also contributing to the growth of the market.
Some of the major companies in the Liver and Kidney Disorders Drugs market include Pfizer, Merck, Novartis, Sanofi, GlaxoSmithKline, AstraZeneca, Bristol-Myers Squibb, and AbbVie. These companies are engaged in the development and production of drugs to treat liver and kidney diseases. Show Less Read more
![º¬Ðß²ÝÊÓƵ](/images/logo.svg"){kind=logo}
![º¬Ðß²ÝÊÓƵ](/images/logo-research-and-markets-print.png"){kind=logo}